Literature DB >> 11259118

GM3 as a novel growth regulator for human gliomas.

E N Noll1, J Lin, Y Nakatsuji, R H Miller, P M Black.   

Abstract

The simple ganglioside GM3 inhibits proliferation and induces apoptosis in proliferating immature rodent CNS cells. To determine whether GM3 influenced the expansion of human neural tumors the effects of GM3 treatment on primary human brain tumors were assayed. Here we demonstrate that GM3 treatment dramatically reduces cell numbers in primary cultures of high-grade human glioblastoma multiforme (GBM) tumors and the rat 9L cell gliosarcoma cell line. By contrast, GM3 treatment had little effect on cell number in cultures of normal human brain. A single injection of GM3 3 days after intracranial implantation of 9L tumor cells in a murine xenograft model system resulted in a significant increase in the symptom-free survival period of host animals. The effects of GM3 were not restricted to GBMs and 9L cells. Cultures of high-grade ependymomas, mixed gliomas, astrocytomas, oligodendrogliomas, and gangliogliomas were all susceptible to GM3 treatment. These results suggest that GM3 may have considerable value as a selectively toxic chemotherapeutic agent for human high-grade gliomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11259118     DOI: 10.1006/exnr.2000.7603

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  12 in total

1.  Fabrication of GM3-enriched sphingomyelin/cholesterol solid-supported lipid membranes on Au/SiO2 plasmonic substrates.

Authors:  G Margheri; R D'Agostino; M Del Rosso; S Trigari
Journal:  Lipids       Date:  2013-04-17       Impact factor: 1.880

2.  Activity of lysosomal exoglycosidases in human gliomas.

Authors:  P Wielgat; U Walczuk; S Szajda; M Bień; L Zimnoch; Z Mariak; K Zwierz
Journal:  J Neurooncol       Date:  2006-05-19       Impact factor: 4.130

3.  Ganglioside GM3 inhibits proliferation and invasion of glioma.

Authors:  Yasunori Fujimoto; Shuichi Izumoto; Tsuyoshi Suzuki; Manabu Kinoshita; Naoki Kagawa; Kouichi Wada; Naoya Hashimoto; Motohiko Maruno; Yuji Nakatsuji; Toshiki Yoshimine
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

4.  Inhibitors of EGFR signaling retard cytotoxicity of fenretinide in rat gliosarcoma cells.

Authors:  Ayesha Zaheer; Shailendra K Sahu; Vincent C Traynelis
Journal:  Neurochem Res       Date:  2007-06-19       Impact factor: 3.996

5.  Thematic review series: sphingolipids. Ganglioside GM3 suppresses the proangiogenic effects of vascular endothelial growth factor and ganglioside GD1a.

Authors:  Purna Mukherjee; Anthony C Faber; Laura M Shelton; Rena C Baek; Thomas C Chiles; Thomas N Seyfried
Journal:  J Lipid Res       Date:  2008-02-20       Impact factor: 5.922

6.  Ganglioside GM3 Is Antiangiogenic in Malignant Brain Cancer.

Authors:  Thomas N Seyfried; Purna Mukherjee
Journal:  J Oncol       Date:  2010-06-20       Impact factor: 4.375

7.  Hepatocyte growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells.

Authors:  Sheng-hua Chu; Yan-bin Ma; Hong Zhang; Dong-fu Feng; Zhi-an Zhu; Zhi-qiang Li; Xian-hou Yuan
Journal:  J Neurooncol       Date:  2007-04-27       Impact factor: 4.130

Review 8.  Gangliosides: The Double-Edge Sword of Neuro-Ectodermal Derived Tumors.

Authors:  Sumeyye Cavdarli; Sophie Groux-Degroote; Philippe Delannoy
Journal:  Biomolecules       Date:  2019-07-27

9.  Efficient synthesis of chloro-derivatives of sialosyllactosylceramide, and their enhanced inhibitory effect on epidermal growth factor receptor activation.

Authors:  Nagako Kawashima; Huanhuan Qu; Marlin Lobaton; Zhenyuan Zhu; Matthieu Sollogoub; Webster K Cavenee; Kazuko Handa; Sen-Itiroh Hakomori; Yongmin Zhang
Journal:  Oncol Lett       Date:  2014-02-17       Impact factor: 2.967

10.  The ganglioside GM3 is associated with cisplatin-induced apoptosis in human colon cancer cells.

Authors:  Tae-Wook Chung; Hee-Jung Choi; Seok-Jo Kim; Choong-Hwan Kwak; Kwon-Ho Song; Un-Ho Jin; Young-Chae Chang; Hyeun Wook Chang; Young-Choon Lee; Ki-Tae Ha; Cheorl-Ho Kim
Journal:  PLoS One       Date:  2014-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.